Find Clinical Trials

Advanced Search

Study phase

Document

Therapeutic area group

Indication

SEARCH CLEAR

180 Results

Protocol Code Study Title Active Substance Study Phase Therapeutic Area
CL2-16257-090 Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy… IVABRADINE / IVABRADINE - S016257 / S016257 / Phase 2 Cardiovascular
CL2-16257-088 Effects of ivabradine IV versus placebo on haemodynamic parameters in patients with a low cardiac… IVABRADINE / IVABRADINE - S016257 / S016257 / Phase 2 Cardiovascular
CL2-16257-073 Evaluation of the effects of oral administration of ivabradine 5 mg and 7.5 mg b.i.d.… IVABRADINE / IVABRADINE - S016257 / S016257 / Phase 2 Cardiovascular
CL2-16257-062 Evaluation of the effects of 3 successive oral dosages (2.5; 5; 7.5 mg b.i.d.) of… IVABRADINE / IVABRADINE - S016257 / S016257 / Phase 2 Cardiovascular
CL2-16257-060 Evaluation of the effects on heart rate, haemodynamic parameters, safety and tolerability of 5 mg… IVABRADINE / IVABRADINE - S016257 / S016257 / Phase 2 Cardiovascular
CL2-16257-053 Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure IVABRADINE / IVABRADINE - S016257 / S016257 / Phase 2 Cardiovascular
CL2-12911-039 A double-blind, multicenter, international randomised study to assess the effects of 4 month-oral administration of… STRONTIUM / STRONTIUM RANELATE / Phase 2 Rhumatology
CL2-09490-157 Assessment of the effects on 24-hour ambulatory blood pressure and the safety of a once-a-day… PERINDOPRIL TERT BUTYLAMINE - PERINDOPRIL ERBUMINE / Phase 2 Cardiovascular
CL2-066913-002 A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in… S066913 / Phase 2 Cardiovascular
CL2-05985-005 Efficacy and safety of the fixed oral low-dose perindopril arginine 3.5 mg/amlodipine 2.5 mg combination… AMLODIPINE / PERINDOPRIL / PERINDOPRIL ARGININE - AMLODIPINE / Phase 2 Cardiovascular
CL2-05720-005 Efficacy and safety assessment of two schemes of oral administration of once-daily extended release metformin… GLICLAZIDE / GLICLAZIDE - METFORMINE - S005720 / METFORMINE / S005720 / Phase 2 Metabolism
CL2-05682-102 Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in… MICRONISED PURIFIED FLAVONOID FRACTION / Phase 2 Cardiovascular
CL2-05682-099 Effects of micronised purified flavonoic fraction on microcirculation in women suffering from chronic venous disease MICRONISED PURIFIED FLAVONOID FRACTION / Phase 2 Cardiovascular
CL1-95005-001 Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer TIPIRACIL / TRIFLURIDINE / TRIFLURIDINE - TIPIRACIL / Phase 1 Oncology
CL1-81694-001 Phase I dose-escalation study of S 81694 administered intravenously in adult patients with advanced/metastatic solid… S081694 / Phase 1 Oncology
CL1-80881-007 An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy,… LUCITANIB / Phase 1-2 Oncology
CL1-78454-009 Phase I dose escalation study of oral administration of Pan-Histone Deacetylase (HDAC) inhibitor S 78454… ABEXINOSTAT / ABEXINOSTAT - S078454 / S078454 / Phase 1 Oncology
CL1-78454-008 Phase I dose-escalation study of oral administration of the Histone Deacetylase (HDAC) Inhibitor S 78454… ABEXINOSTAT / ABEXINOSTAT - S078454 / S078454 / Phase 1 Oncology
CL1-78454-006 Phase I dose-escalation study of S 78454 (HDACi) p.o. in combination with FOLFOX in patients… ABEXINOSTAT / ABEXINOSTAT - S078454 / S078454 / Phase 1 Oncology
CL1-78454-005 Phase I dose-escalation study of oral administration of S 78454 given with a fixed dose… ABEXINOSTAT / ABEXINOSTAT - S078454 / S078454 / Phase 1 Oncology
CL1-78454-002 Phase I dose-escalation study of oral administration of Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in… ABEXINOSTAT / ABEXINOSTAT - S078454 / S078454 / Phase 1 Oncology
CL1-68587-003 A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have… S068587 / S068587 - UCART19 / UCART19 / Phase 1 Oncology
CL1-68587-002 Phase I, open label, dose-escalation study to evaluate the safety, expansion, persistence and biological activity… S068587 / S068587 - UCART19 / UCART19 / Phase 1 Oncology
CL1-64315-001 Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic… S064315 / Phase 1 Oncology
CL1-55746-001 Phase I dose-escalation study of oral administration of the selective Bcl2 inhibitor S55746 in patients… S055746 / Phase 1 Oncology

Servier clinical trials are mainly registered on


EU Clinical Trials Register

The EU Clinical Trials Register contains information on interventional clinical trials on medicines conducted in Europe, which started after 1 May 2004.

SEE MORE

ClinicalTrials.gov

Clinicaltrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.

SEE MORE

ISRCTN registry

The ISRCTN registry is a primary clinical trial registry recognised by WHO and ICMJE that accepts all clinical research studies.

SEE MORE
© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.